Evaluation of SARS-CoV-2-specific Serumparameters in Blood Samples of SARS-CoV-2-seronegative Volunteers as well as former Patients with Healed, Asymptomatic, Mild or Severe COVID-19-Courses (HTXCOV-01B)

Evaluation of SARS-CoV-2-specific Serumparameters in Blood Samples of SARS-CoV-2-seronegative Volunteers as well as former Patients with Healed, Asymptomatic, Mild or Severe COVID-19-Courses (HTXCOV-01B) - COVIAS_B

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025863

Enrollment

Registered

2021-07-29

Start date

2021-06-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1G U09.9G

Interventions

Group 1: one-time blood sampling and survey of SARS-CoV2 negative helathy volunteers (Control) Group 2: one-time blood sampling and survey of SARS-CoV2 positive asymptomatic course Group 3: one-time b

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. the subject/former COVID-19 patient has given consent to participate in the study. 2. The subject/former COVID-19 patient is at least 18 years old and able to give consent. 3. evidence of at least a single positive SARS-CoV-2 smear PCR test (groups b-d) or antibody test for COVID-19. 4. sufficient information for group assignment as well as on the course of COVID-19 disease.

Exclusion criteria

Exclusion criteria: 1. participants who have already been vaccinated against SARS-CoV-2 cannot participate. 2. any illness or condition which, in the opinion of the physician providing the information, does not medically allow the blood sample to be taken.

Design outcomes

Primary

Measure	Time frame
Explorative analysis - Comperative analysis of imunological parameters in serum	—

Secondary

Measure	Time frame
Explorative analysis - Identification of therapeutic targets	—

Countries

Germany

Contacts

Public ContactLaura Brosi

Heidelberg ImmunoTherapeutics GmbH

laura.brosi@hditx.de+49 6221 3919-34

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026